Throughout the COVID-19 pandemic, Saint Luke’s Health System is committed to providing exceptional care for all patients and a safe and healthy atmosphere for our team.

Empagliflozin treatment significantly reduces pulmonary artery (PA) blood pressure in patients with heart failure (HF), show findings from the randomized EMBRACE-HF trial.

Dr. Mikhail Kosiborod, with Saint Luke’s Mid America Heart Institute, and study co-authors say theirs is the first trial to demonstrate a “decongestion effect” of sodium-glucose cotransporter (SGLT)2 inhibition in people with HF via the direct measurement of PA hemodynamics.

Read the full MedwireNews article: Direct ‘decongestion’ effect shown for empagliflozin in HF

Read more >

Related Content

Person, Hair, Nurse, Face, Female, Word
Nicole's story

"What we do is so vital! We have so much power as nurses." Nicole Roberson, Registered NurseNeuroscience ICUSaint Luke's Hospital of Kansas City

Read more >
Person, Doctor, Clothing, Apparel, Lab Coat, Coat, Face, Nurse
Deb's story

Deb Day, Registered Nurse · Anderson County Hospital I am a Saint Luke's Nurse The room to grow, the tools to succeed Nurses are the lifeblood of Saint Luke’s compassionate...

Read more >
Apparel, Clothing, Coat, Lab Coat, Person, Doctor
Danielle's story

"You get those rare moments that you're reminded why you went into this field, and it makes everything so much better." Danielle Hammontree, Certified Family Nurse PractitionerSaint Luke’s East Hospital

Read more >